medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2016, Number 4

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2016; 14 (4)

Onychomycosis and its Influence on Quality of Life

Cobos LD, Fierro AL, Arellano MI, Bonifaz A

Language: Spanish
References: 58
Page: 318-327
PDF size: 161.46 Kb.


ABSTRACT

Onychomycosis is the most frequent nail infection and chronic, it is caused by a variety of microorganisms, but most cases are due to dermatophytes. This disease can have a negative and significant impact on patients quality of life, not only in a physiological way but emotional; it may lead to stigmatization and social exclusion. Nail changes can cause discomfort, pain with often difficulty walking and with prolonged standing; significant limitation of mobility or in certain sporting activities; moreover decrease of tactile functions particularly in the cases of hand onychomycosis. The emotional impact of onychomycosis can be higher, causing embarrassment, loss of confidence and self-esteem, anxiety and depression. The occupation and the socioeconomic status are important determining factors for this manifestations, being as a low socioeconomic status, has a major physiological impact for the type of work the carry out (such as workers, peasants, artisans, etc.); and in cases of higher socioeconomic status, the cosmetic condition with emotional impact is higher, generating psychological repercussions and stigmatization. In both cases diminishing the quality of life.


REFERENCES

  1. Milobratovic‘ D, Jankovic‘ S, Vukicevic‘ J et al. Quality of life in patients with toenail onychomycosis, Mycoses 2013; 56(5): 543-51.

  2. Warshaw EM, Foster JK, Cham PM et al. NailQoL: a quality-of-life instrument for onychomycosis, Int J Dermatol 2007; 46(12): 1279-86.

  3. André J y Achten G. Onychomycosis, Int J Dermatol 1987; 26(8): 481-90.

  4. Scher RK. Onychomycosis: a significant medical disorder, J Am Acad Dermatol 1996; 35(3 Pt2): S2-5.

  5. Tosti A, Baran R, Piraccini BM y Fanti PA. Endonyx onychomycosis: a new modality of nail invasion by dermatophytes, Acta Derm Venereol 1999; 79(1): 52-3.

  6. Hay RJ y Baran R. Onychomycosis: a proposed revision of the clinical classification, J Am Acad Dermatol 2011; 65(6): 1219-27.

  7. Erös N y Károlyi Z. Onychomycosis and its impact on quality of life, Acta Microbiol Immunol Hung 2002; 49(2-3): 347-9.

  8. Bonifaz A, Paredes V, Fierro L et al. Paronychia, Skinmed 2013; 11 (1): 14-6.

  9. Hosuru Subramanya S, Hamal D, Nayak N y Gokhale S. Onychomycosis due to Candida parapsilosis in a child with ventricular septal defect: an unusual predisposition, Case Rep Pediatr 2016; doi: 10.1155/2016/7026068.

  10. Ortega-Springall MF, Arroyo-Escalante S y Arenas R. Onycholisis and chromonychia: a case caused by Trichosporon inkin, Skin Appendage Disord 2016; 1(3): 144-6.

  11. Bonifaz A, Cruz-Aguilar P y Ponce RM. Onychomycosis by molds. Report of 78 cases, Eur J Dermatol 2007; 17(1): 70-2.

  12. Moreno G y Arenas R. Other fungi causing onychomycosis, Clin Dermatol 2010; 28(2): 160-3.

  13. Scher RK. Onychomycosis is more than a cosmetic problem, Br J Dermatol 1994; 130(Supl 43): 15.

  14. Sigurgeirsson B y Baran R. The prevalence of onychomycosis in the global population: a literature study, J Eur Acad Dermatol Venereol 2014; 28(11): 1480-91.

  15. Scher RK, Tavakkol A, Sigurgeirsson B et al. Onychomycosis: diagnosis and definition of cure, J Am Acad Dermatol 2007; 56(6): 939-44.

  16. Welsh O, Vera-Cabrera L y Welsh E. Onychomycosis, Clin Dermatol 2010; 28(2): 151-9.

  17. Gupta AK, Gupta G, Jain HC et al. The prevalence of unsuspected onychomycosis and its causative organisms in a multicentre Canadian sample of 30 000 patients visiting physicians’ offices, J Eu Acad Dermatol Venereol 2016; 30(9): 1567-72.

  18. Gupta AK, Daigle D y Foley KA. The prevalence of culture-confirmed toenail onychomycosis in at-risk patient population, J Eu Acad Dermatol Venereol 2015; 29(6): 1039-44.

  19. Arenas R, Bonifaz A, Padilla MC et al. Onychomycosis. A Mexican survey”, Eu J Dermatol 2010; 20(5): 611-4.

  20. Reich A y Szepietowski JC. Health-related quality of life in patients with nail disorders, Am J Clin Dermatol 2011; 12(5): 313-20.

  21. Tabolli S, Alessandroni L, Gaido J et al. Health-related quality of life and nail disorders, Acta Derm Venereol 2007; 87(3): 255-9.

  22. Lubeck DP, Patrick DL, McNulty P et al. Quality of life of persons with onychomycosis, Qual Life Res 1993; 2(5): 341-8.

  23. Drake LA. Impact of onychomycosis on quality of life, J Am Podiatr Med Assoc 1997; 87(11): 507-11.

  24. Whittman LR y Hay RJ. The impact of onychomycosis on quality of life, Clin Exp Dermatol 1997; 22(2): 87-9.

  25. Drake LA, Scher RK, Smith EB et al. Effect of onychomycosis on quality of life, J Am Acad Dermatol 1998; 38: 702-4.

  26. Lubeck DP. Measuring health-related quality of life in onychomycosis, J Am Acad Dermatol 1998; 38: S64-8.

  27. Drake LA, Patrick DL, Fleckman P et al. The impact of onychomycosis on quality of life: development of an international onychomycosisspecific questionnaire to measure patient quality of life, J Am Acad Dermatol 1999; 41: 189-96.

  28. Lubeck DP, Gause D, Schein JR et al. A health-related quality of life measure for use in patients with onychomycosis: a validation study, Qual Life Res 1999; 8(1-2): 121-9.

  29. Turner RR y Testa MA. Measuring the impact of onychomycosis on patient quality of life, Qual Life Res 2000; 9(1): 39-53.

  30. Shaw JW, Joish VN y Coons SJ. Onychomycosis. Health-related quality of life considerations, Pharmacoeconomics 2002; 20(1): 23-36.

  31. Potter LP, Mathias SD, Raut M et al. The Onycoe-t questionnaire: responsiveness and clinical meaningfulness of a patient-reported outcomes questionnaire for toenail onychomycosis, Health Qual Life Outcomes 2006; 4: 50.

  32. Warshaw EM, Traywick CA, Hoffman AA et al. Naildex: pilot evaluation of an onychodystrophy severity instrument, Mycoses 2008; 51(1): 14-20.

  33. Vanhooteghem O, Szepetiuk G, Paurobally D y Heureux F. Chronic interdigital dermatophytic infection: a common lesion associated with potentially severe consequences, Diabetes Res Clin Pract 2011; 91(1): 23-5.

  34. Bunyaratavej S, Pattanaprichakul P, Leeyaphan C et al. Onychomycosis: a study of self-recognition by patients and quality of life, Indian J Dermatol Venereol Leprol 2015; 81(3): 270-4.

  35. Rich P. Special patient populations: onychomycosis in the diabetic patient, J Am Acad Dermatol 1996; 35: S10-2.

  36. Szepietowski JC, Reich A, Pacan P et al. Evaluation of quality of life in patients with toenail onychomycosis by Polish version of an international onychomycosis-specific questionnaire, J Eur Acad Dermatol Venereol 2007; 21(4): 491-6.

  37. Tosti A y Elewski BE. Treatment of onychomycosis with eficonazole 10% topical solution and quality of life, J Clin Aesthet Dermatol 2014; 7(11): 25-30.

  38. Belyayeva E, Gregoriou S, Chalikias J et al. The impact of nail disorders on quality of life, Eur J Dermatol 2013; 23(3): 366-71.

  39. Szepietowski JC y Reich A. Stigmatization in onychomycosis patients: a population-based study, Mycoses 2009; 52(4): 343-9.

  40. Elewski BE. The effect of toenail onychomycosis on patient quality of life, Int J Dermatol 1997; 36(10): 754-6.

  41. Gregory N. Special patient populations: onychomycosis in the hiv - positive patient, J Am Acad Dermatol 1996; 35: S13-6.

  42. Drake L. Quality of life issues for patients with fungal nail infections, aids Patient Care 1995; 9(Suppl 1): S15-7.

  43. Opp K. Patients’ feelings and attitudes about their nail conditions, aids Patient Care 1995; 9(Suppl 1): S18.

  44. Lateur N, Mortaki A y André J. Two hundred ninety-six cases of onychomycosis in children and teenagers: a 10-year laboratory survey, Pediatr Dermatol 2003; 20(5): 385-8.

  45. Vásquez-del Mercado E y Arenas R. Onychomycosis among children. A retrospective study of 233 Mexican cases, Gac Med Mex 2008; 144(1): 7-10.

  46. García-Romero MT, López-Aguilar E y Arenas R. Onychomycosis in immunosuppressed children receiving chemotherapy, Pediatr Dermatol 2014; 31(5): 618-20.

  47. Lipner SR y Scher RK. Onychomycosis: a small step for quality of care, Curr Med Res Opin 2016; 32(5): 865-7.

  48. Elewski BE. Diagnostic techniques for confirmig onychomycosis, J Am Acad Dermatol 1996; 35: S6-9.

  49. Zane LT, Chanda S, Coronado D y Del Rosso J. Antifungal agents for onychomycosis: new treatment strategies to improve safety, Dermatol Online J 2016; 22(3): 1-11.

  50. Poulakos M, Grace Y, Machin J y Dorval E. Eficonazole and tavaborole: emerging antifungal alternatives for the topical treatment of onychomycosis, J Pharm Pract 2016; pii : 0897190016630904. [Consultado en línea el 25 de septiembre de 2016].

  51. Gupta AK, Daigle D y Foley KA. Network meta-analysis of onychomycosis treatments, Skin Appendage Disord 2015; 1(2): 74-81.

  52. Nair AB, Kim HD, Chakraborty B et al. Ungueal and trans-ungual iontophoretic delivery of terbinafine for the treatment of onychomycosis, J Pharm Sci 2009; 98(11): 4130-40.

  53. Watanabe D, Kawamura C, Masuda Y et al. Successful treatment of toenail onychomycosis with photodynamic therapy, Arch Dermatol 2008; 144(1): 19-21.

  54. Gupta AK, Simpson FC y Heller DF. The future of laser in onychomycosis, J Dermatolog Treat 2016; 27(2): 167-72.

  55. Lateur N. Onychomycosis: beyond cosmetic distress, J Cosmet Dermatol 2006; 5(2): 171-7.

  56. Gupta AK y Studholme C. How do we measure efficacy of therapy in onychomycosis: patient, physician, and regulatory perspective, J Dermatolog Treat 2016; 1-7. [Consultado en línea el 25 de septiembre de 2016].

  57. Smith EB, Stein LF, Fivenson DP y Atillasoy ES, Clinical trial: the safety of terbinafine in patients over the age of 60 years: a multicenter trial in onychomycosis of the feet, Int J Dermatol 2000; 39(11): 861-4.

  58. Firooz A, Khamesipour A y Dowlati Y,Itraconazole pulse therapy improves the quality of life of patients with toenail onychomycosis, J Dermatolog Treat 2003; 14(2): 95-8.




2020     |     www.medigraphic.com